Retraction notice to High Blood miR-802 Is Associated With Poor Prognosis in HCC Patients by Regulating DNA Damage Response 1 (REDD 1)-Mediated Function of T Cells [Oncology Research 27(9) (2019) 1025-1034]
No Abstract
Document Type: Research Article
Affiliations: 1: Department of Hepatobiliary Pancreatic Surgery, First Hospital of Jilin UniversityChangchunP.R. China 2: Department of Cardiology, China-Japan Union Hospital of Jilin UniversityChangchunP.R. China
Publication date: 07 September 2021
Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license.
- Editorial Board
- Information for Authors
- Submit a Paper
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content